At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 807 enrolled
Drug / intervention
Metformin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)
In Brief
A Phase 3 clinical trial evaluating Metformin, LY2189265, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 807 participants across 91 sites in 19 countries.
Detailed Summary
The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Brazil, Canada, Croatia, Czechia, Finland, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionNov 2011
Study CompletionJun 2012
TodayJul 2026
First PostedMay 19, 2010
Enrollment StartMay 1, 2010
Primary CompletionNov 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.1 years ago
Interventions
Metformindrug
LY2189265drug
Placebo (oral)drug
Placebo (subcutaneous)drug